文献速递淋巴瘤白血病

一种用于老年非霍奇金淋巴瘤患者的新型共病评分:三因素风险估计量表

A novel comorbidity score for older adults with non-Hodgkin lymphoma: the 3-factor risk estimate scale.
PubMed 文献 · Blood Adv · 2023-01-01

在监测、流行病学和最终结果-医疗保险数据库中纳入2008至2017年诊断的40486例非霍奇金淋巴瘤患者,用ICD-9/ICD-10编码识别上消化道、内分泌和血管共病并计算三因素风险估计量表(TRES)评分。TRES低、中、高风险组分别占40.8%、37.0%、22.2%,对应中位总生存期分别为8.2年、5.3年和2.9年(P < .001)。TRES与所有非霍奇金淋巴瘤亚型的总生存期及淋巴瘤特异性生存期相关。

要点

  • TRES低、中、高风险组分别占40.8%、37.0%、22.2%,对应中位总生存期分别为8.2年、5.3年和2.9年(P < .001)。
  • TRES与所有非霍奇金淋巴瘤亚型的总生存期相关。
  • 在多变量模型中,TRES与较差的总生存期和淋巴瘤特异性生存期相关。

核心结论

  • TRES具有临床可转化性,且与老年非霍奇金淋巴瘤患者的总生存期和淋巴瘤特异性生存期相关。

研究设计与样本

  • 基于监测、流行病学和最终结果-医疗保险数据库纳入2008至2017年诊断的非霍奇金淋巴瘤患者,共40486例,中位年龄77岁(四分位距71-83岁),中位随访33个月(四分位距13-60个月)。

主要发现

  • 最常见的非霍奇金淋巴瘤亚型为慢性淋巴细胞白血病(28.2%)、弥漫性大B细胞淋巴瘤(27.6%)和滤泡性淋巴瘤(12.6%)。
  • TRES低、中、高风险组分别占40.8%、37.0%、22.2%,对应中位总生存期分别为8.2年、5.3年和2.9年(P < .001)。
  • TRES与所有非霍奇金淋巴瘤亚型的总生存期相关。
  • 在多变量模型中,TRES与较差的总生存期和淋巴瘤特异性生存期相关。

关键数值与推荐

  • TRES低、中、高风险组分别占40.8%、37.0%、22.2%,对应中位总生存期分别为8.2年、5.3年和2.9年(P < .001)。

临床怎么用

  • 对于非霍奇金淋巴瘤患者,指南推荐进行正式的共病评估,但常规实践中很少实施。
  • TRES是一种简单、经过验证的共病标准化评估工具,可能提高对指南的依从性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

For patients with non-Hodgkin lymphoma (NHL), formal comorbidity assessment is recommended but is rarely conducted in routine practice. A simple, validated measure of comorbidities that standardizes their assessment could improve adherence to guidelines. We previously constructed the 3-factor risk estimate scale (TRES) among patients with chronic lymphocytic leukemia (CLL). Here, we investigated TRES in multiple NHL subtypes. In the surveillance, epidemiology, and end results-Medicare database, patients with NHL diagnosed from 2008 to 2017 were included. Upper gastrointestinal, endocrine, and vascular comorbidities were identified using ICD-9/ICD-10 codes to assign TRES scores. Patient characteristic distributions were compared using χ2 or t test. Association of mortality and TRES score was assessed using Kaplan-Meier and multivariable Cox regression model for competing risk. A total of 40 486 patients were included in the study. Median age was 77 years (interquartile range [IQR], 71-83 years). The most frequent NHL subtypes were CLL (28.2%), diffuse large B-cell (27.6%), and follicular lymphoma (12.6%). Median follow-up was 33 months (IQR, 13-60 months). TRES was low, intermediate, and high in 40.8%, 37.0%, and 22.2% of patients, corresponding to median overall survival (OS) of 8.2, 5.3, and 2.9 years (P < .001), respectively. TRES was associated with OS in all NHL subtypes. In multivariable models, TRES was associated with inferior OS and NHL-specific survival. TRES is clinically translatable and associated with OS and lymphoma-specific survival in older adults with NHL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Gordon MJ, Duan Z, Zhao H, et al. A novel comorbidity score for older adults with non-Hodgkin lymphoma: the 3-factor risk estimate scale. Blood Adv. 2023. PMID: 36753602. doi:10.1182/bloodadvances.2022009507

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。